ORCID
- Carroll, Camille: 0000-0001-7472-953X
Abstract
Aim: This subanalysis of the OPTIPARK study aimed to confirm the effectiveness and safety of opicapone in patients with Parkinson's disease and motor fluctuations in clinical practice specifically in the UK and to assess the impact of opicapone on treatment costs. Methods: Patients received opicapone added to levodopa for 6 months. Clinical outcomes were assessed at 3 and 6 months and treatment costs at 6 months. Results: Most patients' general condition improved at 3 months, with sustained improvements reported at 6 months. Opicapone improved motor and non-motor symptoms at both timepoints, was generally well tolerated and reduced total treatment costs by GBP 3719. Conclusion: Opicapone added to levodopa resulted in clinical improvements and reduced treatment costs across UK clinical practice.
DOI
10.2217/nmt-2021-0057
Publication Date
2022-04-01
Publication Title
Neurodegenerative Disease Management
Volume
12
Issue
2
ISSN
1758-2024
Embargo Period
2022-05-26
Organisational Unit
Peninsula Medical School
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
First Page
77
Last Page
91
Recommended Citation
Schofield, C., Chaudhuri, K., Carroll, C., Sharma, J., Pavese, N., Evans, J., Foltynie, T., Reichmann, H., Zurowska, L., Soares-Da-Silva, P., & Lees, A. (2022) 'Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease', Neurodegenerative Disease Management, 12(2), pp. 77-91. Available at: https://doi.org/10.2217/nmt-2021-0057
